The research team, led by Kedir N. Turi of Indiana University with collaborators at Vanderbilt University Medical Center, UT Southwestern, and the University of Wisconsin, mined data from the Infant Susceptibility to Pulmonary Infections and Asthma following Respiratory Syncytial Virus Exposure cohort, known as INSPIRE. Between 2012 and 2014, the study enrolled 1,946 infants in the southeastern United States, of whom 1,166 could be followed to age six. Within that group, 216 children, or 18.5 percent, were diagnosed with asthma by age six using validated questionnaires that captured physician diagnoses, medication use, symptoms, steroid treatment, and acute health care visits. Rather than analyzing the entire cohort, the investigators focused on subsets with layered molecular data: 402 infants had stool microbiome profiles from 16S ribosomal RNA sequencing, 199 had urine metabolomics, and 58 had stool metabolomics. After requiring both microbiome and metabolome data plus the six-year asthma outcome, the overlapping analytical samples shrank to 89 infants for urine and 58 for stool.

Methodologically, the study is a case study in taming high-dimensional biology. The researchers first filtered rare bacterial taxa, retaining 55 amplicon sequence variants after discarding those absent from more than 90 percent of samples, and normalized microbial abundances to correct for sequencing depth. Metabolite measurements, generated with Metabolon’s untargeted ultra-high-performance liquid chromatography-tandem mass spectrometry platforms in positive, negative, and polar ionization modes, were quantile normalized, log transformed, and Pareto scaled. To identify which features actually discriminated between children who later developed asthma and those who did not, the team deployed sparse partial least squares discriminant analysis inside a nested cross-validation framework, with a stratified five-fold outer loop, ten repeats of a five-fold inner loop, and all feature selection confined strictly to training folds to prevent information leakage. Model quality was assessed by the area under the receiver operating characteristic curve, with confidence intervals estimated from 2,000 bootstrap resamples.

The discriminating power of the individual datasets was modest, and the authors are candid about that. The gut microbiome alone yielded a mean AUC of 0.55, essentially barely better than a coin flip, while urine metabolites reached 0.61 and stool metabolites 0.60. But modest prediction was not the point. The goal was to shortlist candidate features for mechanistic hypothesis generation. Among the fifteen most important microbial taxa were Eisenbergiella massiliensis, members of the Clostridium innocuum group, Thomasclavelia ramosa, unclassified Veillonella, Enterobacteriaceae, Staphylococcus, Streptococcus, and Bacteroides species, along with Bilophila wadsworthia and Collinsella aerofaciens. Enrichment analysis showed these taxa overlapped with microbial communities previously implicated in asthma, cystic fibrosis, diabetes, necrotizing colitis, and inflammatory bowel disease, although most disease-pathway terms did not survive correction for multiple testing.

The metabolite side of the ledger told an equally suggestive story. Key urinary discriminators included argininate, kynurenine, 2-methylhippurate, benzoate, and butenoylglycine, hinting at perturbations in retinol metabolism, branched-chain amino acid biosynthesis, and pantothenate and coenzyme A pathways. In stool, the standout compounds were overwhelmingly lipids: cholesterol, fructose, palmitate, myristate, the fatty acid esters of hydroxy fatty acids known as PAHSA and LAHSA, stearoyl sphingomyelin, myristoyl dihydrosphingomyelin, desmosterol, and ceramide. These point toward steroid biosynthesis, fatty acid metabolism, sphingolipid signaling, and caffeine metabolism, pathways tied to epithelial barrier function, membrane organization, and inflammatory regulation. None of the pathway enrichments remained statistically significant after false discovery rate adjustment, a limitation the researchers acknowledge, but the directional signals aligned with known asthma biology.

The heart of the paper lies in the correlations between these shortlisted taxa and metabolites, assessed with Spearman rank correlation and Bonferroni correction. Between stool bacteria and stool metabolites, the relationships were numerous and concentrated in lipid chemistry. Staphylococcus species were negatively correlated with the anti-inflammatory FAHFA lipids PAHSA and LAHSA, yet positively correlated with cholesterol and desmosterol. Enterobacteriaceae tracked with myristoyl dihydrosphingomyelin, Veillonella with stearoyl sphingomyelin, and Thomasclavelia ramosa was inversely related to ceramide. Dorea species correlated negatively with stearate, Bacteroides with 3,7-dimethylurate, and the Clostridium innocuum group with 5,6-dihydrothymine. By contrast, the cross-compartment analysis linking stool bacteria to urine metabolites was strikingly weak, with only two significant negative correlations: Collinsella aerofaciens with 2-methylhippurate and Bilophila wadsworthia with argininate.

Interpreting these patterns, the authors emphasize the ecology of the newborn gut rather than any single causal arrow. Staphylococcus is a signature genus of the early facultative-anaerobe stage of colonization and a dominant member of the breast milk microbiome, while cholesterol and desmosterol are abundant in breast milk and crucial for infant growth and immune cell function. Prior laboratory work has shown that cholesterol stimulates the proliferation of Staphylococcus species, which can scavenge host lipids to fuel growth. The observed positive correlation between the bacterium and these sterols may therefore reflect a milk-fed gut environment in which diet, microbial succession, and host lipid metabolism co-vary, rather than a direct mechanistic relationship. Similarly, the negative association between Staphylococcus and FAHFAs, lipid mediators with anti-inflammatory and immune-modulating properties that also occur in human milk, invites speculation that early colonization patterns influence the availability of these protective compounds.

The sphingolipid and purine findings reinforce the dietary thread. Sphingomyelins are among the most abundant lipids in human breast milk and infant formula, and Enterobacteriaceae and Veillonella are classic pioneer colonizers that thrive during the milk-dominated stage of infancy, so their positive correlations with sphingomyelin species may simply mark a shared developmental timeline. The inverse relationship between Bacteroides and 3,7-dimethylurate, a byproduct of xanthine and caffeine-like compounds, is particularly intriguing: xanthines reach infants through maternal caffeine passing into breast milk or through formula ingredients, while Bacteroides species, which flourish on human milk oligosaccharides and are acquired in greater abundance during vaginal birth, may accelerate the clearance of these compounds. To check whether these interpretations were plausible, the team ran the eleven significantly correlated metabolites through the MetOrigin database, which assigns putative sources. Seven were flagged as likely co-metabolised by host and microbiome, two as solely microbial, and source enrichment pointed overwhelmingly to food-derived compounds processed through microbial metabolism.

The authors are careful to frame the work as exploratory. The metabolomics subsample was deliberately enriched for early wheeze and allergic sensitization, so the discrimination metrics do not represent predictive performance in the general population. The 16S rRNA sequencing resolves bacteria only to genus level in many cases, stool sampling captures luminal rather than mucosa-associated communities, the stool metabolome subset of 58 infants is small enough that even nested cross-validation may yield unstable estimates, and no direct dietary intake data were collected, making all diet-related discussion speculative. Correlations, by definition, establish neither direction nor causation. Still, by following a longitudinally characterized birth cohort from the first months of life to a hard clinical outcome at age six, and by integrating microbiome and metabolome data from both gut and urine, the study offers a concrete, testable hypothesis: the infant gut environment shaped by feeding mode and microbial colonization produces a metabolite milieu, rich in diet-derived lipids and microbial co-metabolites, that helps calibrate the developing immune system and, in doing so, may tilt the odds toward or away from childhood asthma. Confirmation will require replication and experiments, but the biochemical suspects are now named.

Subject of Research: Integrative analysis of the infant gut microbiome and metabolome in relation to childhood asthma risk

Article Title: Exploratory integrative analysis of infant gut microbiome and metabolome suggests diet- and microbiome-derived metabolites associated with childhood asthma

Article References: Turi, K. N., Wu, X., Li, Y., Rosas-Salazar, C., Gebretsadik, T., Shilts, M. H., Das, S. R., Gern, J., Xu, Y., & Hartert, T. V. (2026). Exploratory integrative analysis of infant gut microbiome and metabolome suggests diet- and microbiome-derived metabolites associated with childhood asthma. Metabolomics, 22(5), Article 162. https://doi.org/10.1007/s11306-026-02540-3

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02540-3

Keywords: asthma, gut microbiome, metabolomics, infants, birth cohort, breast milk, FAHFA lipids, sphingolipids, Staphylococcus, Bacteroides, gut-lung axis, 16S rRNA sequencing

A new study published in the journal Gut Pathogens by Deepika Pateriya, Anjli Tanwar and Vineet K. Sharma of the MetaBioSys Group at the Indian Institute of Science Education and Research Bhopal offers one of the most comprehensive portraits of the human resistome to date. The work, conducted as an open-access genomic and metagenomic analysis, was designed to address persistent gaps in the field. Most previous surveys of gut resistance genes have focused on Western cohorts, leaving the diversity of non-Western populations underexplored. The Indian team set out to quantify how resistance genes are distributed across bacterial taxa, how their abundance differs between healthy individuals and disease patients, and how the oral and gut microbiomes compare as resistance reservoirs.

The scale of the analysis is striking. The researchers assembled genomic data from 4,744 species-representative gut bacterial genomes and 452 oral bacterial genomes to examine which organisms carry resistance determinants and how many genes each species harbors. On top of this reference-based foundation, they layered metagenomic sequencing data from 10,230 individuals drawn from 58 independent studies. This metagenomic cohort included 5,388 samples from healthy individuals and 4,842 samples associated with disease, providing the statistical power needed to detect consistent patterns across populations, countries and clinical conditions rather than idiosyncrasies of any single dataset.

One of the study’s clearest findings is that the gut resistome is not a uniform feature of humanity. The researchers documented substantial variation in the composition and abundance of resistance genes across population groups and countries, indicating that geography, lifestyle and local microbial ecology all leave measurable imprints on the resistance genes carried by gut bacteria. Equally notable was the comparison between body sites: the oral microbiome exhibited a distinctly different resistome profile from the gut, with a generally lower prevalence of antibiotic resistance genes. This contrast suggests that the gut, with its dense microbial biomass and constant exposure to diet, bile acids and antibiotics taken orally, provides particularly fertile ground for the accumulation and maintenance of resistance determinants.

Disease emerged as another powerful axis of variation. Across multiple datasets included in the analysis, the abundance of antibiotic resistance genes was generally higher in samples from patients with inflammatory bowel disease than in samples from healthy individuals. This association is consistent with the idea that inflamed intestinal environments, often characterized by dysbiosis, oxidative stress and shifts in bacterial community composition, favor the expansion of resistant organisms. It also raises clinically important questions about whether elevated resistome burdens in inflammatory bowel disease contribute to the recurrent infections and treatment complications that complicate the management of these conditions, or whether they are a consequence of antibiotic use and microbial imbalance during flare-ups.

The taxonomic dimension of the study revealed a division of labor within the gut community. Pathogenic genera such as Enterobacter, Citrobacter, Escherichia and Klebsiella carried the highest number of resistance genes, including clinically relevant ARGs that compromise the efficacy of important drug classes. These opportunistic pathogens, many of which belong to the family Enterobacteriaceae and are notorious causes of hospital-acquired infections, appear to be the primary vehicles for clinically dangerous resistance in the gut. However, the researchers found that the baseline resistome of a healthy gut is largely maintained by abundant commensal organisms, particularly members of the genera Bacteroides and Prevotella. These benign, numerically dominant bacteria carry their own repertoire of resistance genes, contributing to a persistent background level of resistance even in people who have never been hospitalized.

Perhaps the most mechanistically revealing observation concerned the overlap between commensals and pathogens. The study identified resistance genes shared between commensal and pathogenic bacteria, a pattern that provides clues to horizontal gene transfer, the process by which mobile genetic elements such as plasmids, transposons and integrons shuttle genes between unrelated organisms. Horizontal gene transfer is the dominant engine of resistance dissemination, and the gut, with its extraordinarily dense and diverse microbial population, is considered one of the most active arenas for this exchange on the planet. The shared gene repertoire documented in this study suggests that commensal organisms may serve as intermediaries, acquiring resistance genes from the wider environment and eventually passing them to pathogens that can cause disease.

A subtle but consequential point in the paper is that population-level differences in ARG composition appeared to be linked to microbial community structure. In other words, the resistance genes found in a given population are not distributed randomly; they track the particular species and strains that dominate the local gut ecosystem. Populations whose microbiomes are enriched for different sets of bacteria will, as a consequence, carry different resistance gene profiles. This finding reframes resistome variation as an ecological phenomenon: to understand why resistance genes differ between countries and cohorts, researchers must first understand why the underlying microbial communities differ, which in turn reflects diet, environment, hygiene, antibiotic exposure history and host genetics.

The inclusion of non-Western cohorts gives the study particular significance for global health. Antimicrobial resistance is projected to cause millions of deaths annually in the coming decades, and the burden falls disproportionately on low- and middle-income countries where antibiotic access, regulation and sanitation differ from wealthy nations. If the gut resistomes of these populations are shaped by distinct microbial communities and environmental exposures, then resistance surveillance and intervention strategies modeled exclusively on Western data may fail to capture the true global picture. By profiling resistance genes across 58 studies spanning multiple countries, the Bhopal team has helped build the comparative foundation that global resistome monitoring requires, demonstrating that both pathogens and commensals must be tracked to understand how resistance is maintained and disseminated at the population level.

Technically, the study exemplifies the power of combining genome-resolved and metagenome-wide approaches. The use of species-representative genomes allowed the authors to assign resistance genes to specific bacterial taxa with confidence, distinguishing between genes carried by a handful of pathogens and those woven into the fabric of the commensal community. The large-scale metagenomic analysis, meanwhile, enabled quantitative comparisons of ARG abundance across health states and populations, generating statistically robust contrasts such as the elevated resistance burden in inflammatory bowel disease. Together, these approaches show how the resistome can be mapped with a resolution that connects individual genes to individual organisms to entire communities.

The implications of the work extend in several directions. For clinicians, the identification of Enterobacter, Citrobacter, Escherichia and Klebsiella as the dominant carriers of clinically relevant resistance genes reinforces the value of surveillance for these organisms in vulnerable patients. For microbiome scientists, the demonstration that commensals such as Bacteroides and Prevotella underpin the baseline resistome suggests that strategies aimed at reducing resistance transmission may need to consider the entire community, not just pathogens. And for public health authorities, the population-level variation in resistome composition argues for geographically diverse resistance monitoring programs. The authors emphasize that their findings illuminate the ecological and population-level factors shaping the gut resistome, highlighting the dual roles of pathogens and commensals in maintaining and spreading antimicrobial resistance, a reminder that the fight against antibiotic resistance will be won or lost in part within the human gut itself.

Subject of Research: Dynamics of antibiotic resistance genes in the human gut microbiome across global populations

Article Title: Insights into the dynamics of antibiotic resistance genes in the human gut microbiome across populations

Article References: Pateriya, D., Tanwar, A., & Sharma, V. K. (2026). Insights into the dynamics of antibiotic resistance genes in the human gut microbiome across populations. Gut Pathogens, 18(1), Article 76. https://doi.org/10.1186/s13099-026-00860-2

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00860-2

Keywords: antibiotic resistance, resistome, gut microbiome, metagenomics, horizontal gene transfer, inflammatory bowel disease, oral microbiome, antimicrobial resistance, Bacteroides, Klebsiella, population variation, microbial ecology